• Something wrong with this record ?

Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years' multi-stakeholder dialogue on improving access in Europe via MoCA

M. Cavaller-Bellaubi, W. Hughes-Wilson, Š. Kubinová, M. Van de Casteele, EJ. Van Lente, E. Degortes, J. Pontén, HG. Eichler, Y. Le Cam, S. Boselli, A. Bucsics

. 2023 ; 18 (1) : 144. [pub] 20230612

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23011069

BACKGROUND: The Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA) was established in 2013 with the intention of developing a coordinated mechanism between volunteering EU stakeholders and developers of Orphan Medicinal Products (OMPs) to support the exchange of information aimed at enabling informed decisions on pricing and reimbursement at Member State level and to evaluate the value of an OMP based on a Transparent Value Framework. The objective of the collaborative approach was to support more equitable access to authorised therapies for people living with rare diseases, rational prices for payers and more predictable market conditions for OMP developers. Over the past 10 years, the MoCA has conducted a series of pilot projects, examining a variety of different products and technologies at different stages of development; and with contributions from a variety of patient representatives, participation from EU payers from a range of Member States and, recently, with EUnetHTA members and the European Medicines Agency participating in the meetings as observers. RESULTS: 10 years on from the establishment of the MoCA, the European landscape has significantly evolved, not only in the field of drug development with increasingly transformative therapies based on novel technologies, but also in terms of larger numbers of approved treatments, increased budget impact and the resulting associated uncertainties; as well as in terms of stakeholder collaboration and interactions. The value of early dialogue with OMP developers, including the EU payer community via their national decision-making authorities, is a key element within this early interaction and contributes to identifying, managing and reducing uncertainties allowing a prospectively planned approach earlier in development and, consequently, to support more timely, sustainable and equitable access to new OMPs, particularly where there is a high unmet medical need. CONCLUSIONS: The voluntary, informal nature of the MoCA interactions creates a flexible framework for non-binding dialogue. A forum for such interactions is needed to achieve the aims of the MoCA and both to support healthcare systems in planning as well as to underpin timely, equitable and sustainable access to new therapies for patients with rare diseases within the EU.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011069
003      
CZ-PrNML
005      
20230801132807.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13023-023-02774-7 $2 doi
035    __
$a (PubMed)37308991
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Cavaller-Bellaubi, Maria $u EURORDIS - Rare Diseases Europe, Paris, France. maria.cavaller@eurordis.org $u MoCA Steering Committee Members, Brussels, Belgium. maria.cavaller@eurordis.org $1 https://orcid.org/0000000266586863
245    10
$a Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years' multi-stakeholder dialogue on improving access in Europe via MoCA / $c M. Cavaller-Bellaubi, W. Hughes-Wilson, Š. Kubinová, M. Van de Casteele, EJ. Van Lente, E. Degortes, J. Pontén, HG. Eichler, Y. Le Cam, S. Boselli, A. Bucsics
520    9_
$a BACKGROUND: The Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA) was established in 2013 with the intention of developing a coordinated mechanism between volunteering EU stakeholders and developers of Orphan Medicinal Products (OMPs) to support the exchange of information aimed at enabling informed decisions on pricing and reimbursement at Member State level and to evaluate the value of an OMP based on a Transparent Value Framework. The objective of the collaborative approach was to support more equitable access to authorised therapies for people living with rare diseases, rational prices for payers and more predictable market conditions for OMP developers. Over the past 10 years, the MoCA has conducted a series of pilot projects, examining a variety of different products and technologies at different stages of development; and with contributions from a variety of patient representatives, participation from EU payers from a range of Member States and, recently, with EUnetHTA members and the European Medicines Agency participating in the meetings as observers. RESULTS: 10 years on from the establishment of the MoCA, the European landscape has significantly evolved, not only in the field of drug development with increasingly transformative therapies based on novel technologies, but also in terms of larger numbers of approved treatments, increased budget impact and the resulting associated uncertainties; as well as in terms of stakeholder collaboration and interactions. The value of early dialogue with OMP developers, including the EU payer community via their national decision-making authorities, is a key element within this early interaction and contributes to identifying, managing and reducing uncertainties allowing a prospectively planned approach earlier in development and, consequently, to support more timely, sustainable and equitable access to new OMPs, particularly where there is a high unmet medical need. CONCLUSIONS: The voluntary, informal nature of the MoCA interactions creates a flexible framework for non-binding dialogue. A forum for such interactions is needed to achieve the aims of the MoCA and both to support healthcare systems in planning as well as to underpin timely, equitable and sustainable access to new therapies for patients with rare diseases within the EU.
650    _2
$a lidé $7 D006801
650    12
$a vzácné nemoci $7 D035583
650    12
$a rozpočty $7 D002017
650    _2
$a vyvíjení léků $7 D000076722
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hughes-Wilson, Wills $u Mereo BioPharma Plc, London, United Kingdom $u MoCA Steering Committee Members, Brussels, Belgium
700    1_
$a Kubinová, Šárka $u State Institute for Drug Control, Prague, Czech Republic $u MoCA Steering Committee Members, Brussels, Belgium
700    1_
$a Van de Casteele, Marc $u Rijksinstituut Voor Ziekte- en Invaliditeitsverzekering (RIZIV-INAMI), Brussels, Belgium $u Medicine Evaluation Committee (MEDEV), Brussels, Belgium $u MoCA Steering Committee Members, Brussels, Belgium
700    1_
$a Van Lente, Evert Jan $u Medicine Evaluation Committee (MEDEV), Brussels, Belgium $u MoCA Steering Committee Members, Brussels, Belgium
700    1_
$a Degortes, Emanuele $u Menarini Group, Florence, Italy
700    1_
$a Pontén, Johan $u Medicine Evaluation Committee (MEDEV), Brussels, Belgium $u MoCA Steering Committee Members, Brussels, Belgium
700    1_
$a Eichler, Hans-Georg $u Association of Austrian Social Insurances, Vienna, Austria
700    1_
$a Le Cam, Yann $u EURORDIS - Rare Diseases Europe, Paris, France $u MoCA Steering Committee Members, Brussels, Belgium
700    1_
$a Boselli, Simone $u EURORDIS - Rare Diseases Europe, Paris, France $u MoCA Steering Committee Members, Brussels, Belgium
700    1_
$a Bucsics, Anna $u MoCA Steering Committee Members, Brussels, Belgium
773    0_
$w MED00165365 $t Orphanet journal of rare diseases $x 1750-1172 $g Roč. 18, č. 1 (2023), s. 144
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37308991 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132803 $b ABA008
999    __
$a ok $b bmc $g 1963464 $s 1197334
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 18 $c 1 $d 144 $e 20230612 $i 1750-1172 $m Orphanet journal of rare diseases $n Orphanet J Rare Dis $x MED00165365
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options